Senolytic Drug - ScienceChronicle
ScienceChronicle

Senolytic Drug

2nd Generation Senolytic Drug Derived from Navitoclax Shows Promising Results for Osteoarthritis and IPF
May 18, 2023
2nd Generation Senolytic Drug Derived from Navitoclax Shows Promising Results for Osteoarthritis and IPF
A new study conducted by researchers at the University of Birmingham has shown promising results for a 2nd generation senolytical drug derived from navitoclax in treating osteoarthritis and idiopathic pulmonary fibrosis (IPF).
Support us

Science Chronicle